NDATRANSDERMALFILM, EXTENDED RELEASE
Approved
Jan 2013
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
13
Data completeness
4/8 — Partial
OXYTROL FOR WOMEN (oxybutynin) by AbbVie is cholinergic muscarinic antagonists [moa]. Approved for overactive bladder, neurogenic bladder, urge urinary incontinence. First approved in 2013.
Drug data last refreshed Yesterday
Mechanism of Action
Cholinergic Muscarinic Antagonists
Pharmacologic Class:
Cholinergic Muscarinic Antagonist
Indications (3)
Worked on OXYTROL FOR WOMEN at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.